temozolomide has been researched along with n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Li, A; Liu, T; Xin, Y; Xu, Y | 1 |
1 other study(ies) available for temozolomide and n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
Article | Year |
---|---|
Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzamides; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Humans; Janus Kinase 2; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Xenograft Model Antitumor Assays | 2019 |